Eplerenone nanocrystals engineered by controlled crystallization for enhanced oral bioavailability.

Area of Science:

• Pharmaceutical Sciences
• Materials Science
• Drug Delivery

Background:

• Poor aqueous solubility of eplerenone (EPL) limits its oral bioavailability.
• Developing effective delivery systems is crucial for poorly water-soluble drugs.

Purpose of the Study:

• To develop and characterize eplerenone nanocrystals (EPL-NCs) for enhanced solubility, dissolution, and oral bioavailability.
• To evaluate the safety profile of the developed EPL-NCs.

Main Methods:

• EPL-NCs were prepared using a controlled crystallization technique during freeze-drying.
• A D-optimal combined mixture design was employed for process optimization.
• Characterization included particle size, morphology (SEM), thermal behavior (DSC), crystalline structure (PXRD), saturation solubility, dissolution studies, in vivo pharmacokinetics, and acute toxicity.

Main Results:

• Optimized EPL-NCs exhibited a mean particle size of 46.8 nm with an elongated parallelepiped shape.
• Saturation solubility increased 17-fold, and dissolution rate dramatically improved (95% in 10 min vs. 29% for EPL powder).
• EPL-NCs demonstrated enhanced oral bioavailability (higher AUC, Cmax; lower Tmax) and no acute toxicity.

Conclusions:

• Controlled crystallization is a viable method for producing eplerenone nanocrystals.
• EPL-NCs effectively improve the solubility, dissolution, and oral bioavailability of eplerenone.
• This nanocrystal formulation presents a promising approach for delivering poorly water-soluble drugs.